The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Carbidopa/Levodopa Orion 12.5 mg/50 mg tablets

Orion CorporationPA1327/021/001

Main Information

Trade NameCarbidopa/Levodopa Orion 12.5 mg/50 mg tablets
Active SubstancesCarbidopa monohydrate
Dosage FormTablet
Licence HolderOrion Corporation
Licence NumberPA1327/021/001

Group Information

ATC CodeN04BA02 levodopa and decarboxylase inhibitor


License statusAuthorised
Licence Issued16/12/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back